{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038030","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.396781+00:00","generated_at":"2026-06-04T06:54:07.640119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Achieve Life Sciences reports 2023 net loss of $29.8M; FDA agrees on NDA path for cytisinicline","bullets":["Net loss Q4 2023: $5.5M; full-year 2023 net loss: $29.8M; operating expenses $27.3M.","Cash $15.6M at Dec 31, 2023; pro forma $71.8M after Feb 2024 equity financing of up to $124.2M.","FDA agreed single open-label safety study (ORCA-OL) is sufficient; NDA submission expected H1 2025.","Phase 3 ORCA-2/3 and Phase 2 ORCA-V1 data at SRNT: 69% of cytisinicline users quit smoking; 97% would recommend.","Shares outstanding as of March 28, 2024: 34,251,911."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038030","json":"https://secwatch.observer/filing/0000950170-24-038030.json","markdown":"https://secwatch.observer/filing/0000950170-24-038030.md","text":"https://secwatch.observer/filing/0000950170-24-038030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017024038030/0000950170-24-038030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017024038030/achv-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:54:07.640119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04b8e37b320664e318a161abdafa2bab2dce6153","claim":"ACHIEVE LIFE SCIENCES, INC. reported fourth quarter and year ended December 31, 2023 results: net income $5.5 million and $29.8 million.","evidence_excerpt":"Total net loss for the fourth quarter and year ended December 31, 2023 was $5.5 million and $29.8 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017024038030/0000950170-24-038030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"$5.5 million and $29.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}